Maria Baer
Director of Hematologic Malignancies, Hematologist · Univ of Maryland Sch of Med
Credentials: · · · · ·
History
- 1985–1986
Hematology Vanderbilt University
- 1979–1982
-B.A. Harvard University
- 1975–1979
Research
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
The Lancet · 2021 · 704 citations
Journal of Clinical Oncology · 2010 · 637 citations
- CB
61 papers
- MW
50 papers
- VD
44 papers
41 papers
- JK
40 papers
36 papers
33 papers
32 papers · 1 as a fellow
Grants
- 2008–2026
University of Maryland Greenebaum Cancer Centersupport Grant
National Cancer Institute · P30
Project lead · $422.2K · University of Maryland Baltimore
- 2021–2026
Enhancing FLT3 Inhibitor Efficacy in Acute Myeloid Leukemia with FLT3-ITD
Department of Veterans Affairs · I01
Contact PI · Baltimore Va Medical Center
- 2014–2019
Inhibition of Pim Kinases in Acute Myeloid Leukemia
Department of Veterans Affairs · I01
Contact PI · Baltimore Va Medical Center
- 2007–2010
National Cancer Institute · R21
Contact PI · $345.6K · University of Maryland Baltimore
Clinical trials
- 2016–2020
Decitabine and Talazoparib in Untreated AML and R/R AML
Principal investigator · Completed · Phase 1, Phase 2
University of Maryland, Baltimore
- 2004–2007
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML
Principal investigator · Completed · Phase 2
Eleos, Inc.
- 2006
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
Study chair · Active not recruiting
Alliance for Clinical Trials in Oncology
- 2002–2005
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Study chair · Completed · Phase 2
Alliance for Clinical Trials in Oncology